Ischemic And Bleeding Risk Assessment After TAVR

Launched by NIGUARDA HOSPITAL · Aug 13, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the risks of blood clots and bleeding in patients who undergo a procedure called Transcatheter Aortic Valve Replacement (TAVR) for severe aortic valve narrowing, a condition known as aortic stenosis. The goal is to better understand how different types of blood-thinning treatments and the patient's overall health can affect these risks after the procedure. Researchers are looking at how the type of valve used and certain blood test results can influence the likelihood of complications over time.

To participate in this trial, you must be an adult with severe aortic stenosis who is scheduled for TAVR. The study will track changes in your blood-thinning treatment at specific times after the procedure—at one month, three months, and one year. It's important to know that patients who do not survive the initial procedure or those on a specific type of blood-thinning therapy will not be eligible. Participants can expect regular follow-ups and monitoring to assess their health and any changes in their treatment plan.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • All patients with severe aortic stenosis undergoing TAVR.
• • Availability of changes in antithrombotic therapy at 1 month, 90 days, and 1 year after TAVR.
• • Exclusion Criteria
• • Patients who died during the index procedure
• • Patients in triple antithrombotic therapy at discharge
• • Patients with a known prognosis less than 1 year at the time of TAVR